Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 6/2014

01-06-2014 | Original Article

Immediate Radical Therapy or Conservative Treatments When Meeting the Milan Criteria for Advanced HCC Patients After Successful TACE

Authors: L. Jiang, J. Y. Lei, W. T. Wang, L. N. Yan, B. Li, T. F. Wen, M. Q. Xu, J. Y. Yang, Y. G. Wei

Published in: Journal of Gastrointestinal Surgery | Issue 6/2014

Login to get access

Abstract

Background and aims

Many advanced hepatocellular carcinoma (HCC) cases can be successfully downstaged into the Milan criteria; however, immediate radical therapy cannot be applied to all such patients for various reasons. Of the patients who are not eligible for immediate radical therapy, some accept repeated downstaging therapies and some undergo persistent observation. The aim of the present study was to compare long-term survival between these two groups of patients.

Patients and Methods

Between August 2003 and October 2008, 156 HCC patients successfully received downstaging therapy resulting in compliance with the Milan criteria. Of those, 98 cases accepted radical therapies, including liver transplantation (LT), resection, or radiofrequency ablation (RFA) (group 1), and 58 cases underwent repeated transcatheter arterial chemoembolization (TACE) or persistent observation (group 2). The baseline characteristics, demographic data, downstaging protocol, and information on long-term outcomes were collected and compared.

Results

No significant differences were observed in the patient demographic data, downstaging protocols, or tumor characteristics between the two groups. The 1-, 3-, and 5-year overall survival rates were 92.9, 82.7, and 78.6 %, respectively, in group 1, whereas these rates were 82.8, 65.5, and 48.3 %, respectively, in group 2 (P = 0.046). Among the 58 patients in group 2, the 1-, 3-, and 5-year overall survival rates were 92.3, 65.4, and 46.2 %, respectively, in the repeated TACE group, and 81.3, 65.6, and 50 %, respectively, in the persistent observation group (P = 0.783).

Conclusion

Immediate radical therapy should be the first choice for advanced HCC patients who undergo successful TACE, and repeated TACE is unnecessary.
Literature
1.
2.
go back to reference Kin JM, Kwon CH, Joh JW, et al. Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation? Transplant Proc. 2010;42(3):821–4CrossRef Kin JM, Kwon CH, Joh JW, et al. Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation? Transplant Proc. 2010;42(3):821–4CrossRef
3.
go back to reference Lo CM, Ngan H, Tso WK, et al. Randomized controlled trail of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71PubMedCrossRef Lo CM, Ngan H, Tso WK, et al. Randomized controlled trail of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71PubMedCrossRef
4.
go back to reference Llovet JM, Real MI, Montana X, Barcelona Liver Cancer Group, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359;1734–9PubMedCrossRef Llovet JM, Real MI, Montana X, Barcelona Liver Cancer Group, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359;1734–9PubMedCrossRef
5.
go back to reference Yao FY, Kerlan Jr RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48:819–27PubMedCrossRef Yao FY, Kerlan Jr RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48:819–27PubMedCrossRef
6.
go back to reference Gordon-Weeks AN, Snaith A, Petrinic T, et al. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg. 2011;98(9):1201–8PubMedCrossRef Gordon-Weeks AN, Snaith A, Petrinic T, et al. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg. 2011;98(9):1201–8PubMedCrossRef
7.
go back to reference Herrero JI, Sangro B, Pardo F, et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl. 2008;14:272–8PubMedCrossRef Herrero JI, Sangro B, Pardo F, et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl. 2008;14:272–8PubMedCrossRef
8.
go back to reference Yao FY, Kinkhabwala M, LaBerge JM, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5(Pt1):795–804PubMedCrossRef Yao FY, Kinkhabwala M, LaBerge JM, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5(Pt1):795–804PubMedCrossRef
10.
go back to reference Silva M, Moya A, Berenguer M, et al. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl. 14:1449–60 Silva M, Moya A, Berenguer M, et al. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl. 14:1449–60
11.
go back to reference Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9PubMedCrossRef Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9PubMedCrossRef
12.
go back to reference Chapman WC, Majella Doyle MB, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg. 2008;248(4):617–25PubMed Chapman WC, Majella Doyle MB, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg. 2008;248(4):617–25PubMed
13.
go back to reference Jiang L, Yan L, Li B, et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant. 2010;10(8):1861–9PubMedCrossRef Jiang L, Yan L, Li B, et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant. 2010;10(8):1861–9PubMedCrossRef
14.
go back to reference Radionics TM, Burlington MA, Lei JY, Yan LN, Wang WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. World J Gastroenterol. 2013;19(27):4400–8CrossRef Radionics TM, Burlington MA, Lei JY, Yan LN, Wang WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. World J Gastroenterol. 2013;19(27):4400–8CrossRef
15.
go back to reference Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC confirming to the Milan criteria. Ann Surg. 2010;252(6):903–12PubMedCrossRef Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC confirming to the Milan criteria. Ann Surg. 2010;252(6):903–12PubMedCrossRef
16.
go back to reference Lei J, Wang W, Yan L. Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization. J Gastrointest Surg. 2013 17(10):1752–9PubMedCrossRef Lei J, Wang W, Yan L. Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization. J Gastrointest Surg. 2013 17(10):1752–9PubMedCrossRef
17.
go back to reference Herber S, Schneider J, Brecher B, et al. TACE: therapy of the HCC before liver transplantation-experiences. Rofo. 2005;177(5):681–90PubMedCrossRef Herber S, Schneider J, Brecher B, et al. TACE: therapy of the HCC before liver transplantation-experiences. Rofo. 2005;177(5):681–90PubMedCrossRef
18.
go back to reference Lei J, Yan L. Comparison between living donor liver transplantation recipients who me the Milan and UCSF criteria after successful downstaging therapies. J Gastrointest Surg. 2012;16(11):2120–5PubMedCrossRef Lei J, Yan L. Comparison between living donor liver transplantation recipients who me the Milan and UCSF criteria after successful downstaging therapies. J Gastrointest Surg. 2012;16(11):2120–5PubMedCrossRef
19.
go back to reference Lei J, Wang W, Yan L. Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria. J Gastrointest Surg. 2013;17(8):1440–6PubMedCrossRef Lei J, Wang W, Yan L. Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria. J Gastrointest Surg. 2013;17(8):1440–6PubMedCrossRef
20.
go back to reference Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7(11):2587–96PubMedCrossRef Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7(11):2587–96PubMedCrossRef
21.
go back to reference Lei JY, Wang WT, Yan LN. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. World J Gastroenterol. 2013;19(36):6077–83PubMedCentralPubMedCrossRef Lei JY, Wang WT, Yan LN. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. World J Gastroenterol. 2013;19(36):6077–83PubMedCentralPubMedCrossRef
22.
go back to reference Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85(12):1726–32PubMedCrossRef Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85(12):1726–32PubMedCrossRef
23.
go back to reference Lei JY, Yan LN, Wang WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. World J Gastroenterol. 2013;19(27):4400–8PubMedCentralPubMedCrossRef Lei JY, Yan LN, Wang WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. World J Gastroenterol. 2013;19(27):4400–8PubMedCentralPubMedCrossRef
24.
go back to reference Vitale A, D’Amico F, Frigo AC, et al. Response to therapy as a criterion awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol. 2010;17(9):2290–302PubMedCrossRef Vitale A, D’Amico F, Frigo AC, et al. Response to therapy as a criterion awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol. 2010;17(9):2290–302PubMedCrossRef
25.
go back to reference Bargellini I, Bozzi E, Campani D, et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013;82(5):e212–8PubMedCrossRef Bargellini I, Bozzi E, Campani D, et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013;82(5):e212–8PubMedCrossRef
26.
go back to reference Toso C, Menth G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010;52(6):930–6PubMedCrossRef Toso C, Menth G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010;52(6):930–6PubMedCrossRef
27.
go back to reference Otto G, Schuchmann M, Hoppe-Lotichius M, et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE. J Hepatol. 2013;59(2):279–84PubMedCrossRef Otto G, Schuchmann M, Hoppe-Lotichius M, et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE. J Hepatol. 2013;59(2):279–84PubMedCrossRef
29.
go back to reference Teizi E, Golfieri R, Piscaglia F, et al. Response rate and clinical outcome of HCC after first and repeated C TACE performed “on demand”. J Hepatol. 2012;57(6):1258–67CrossRef Teizi E, Golfieri R, Piscaglia F, et al. Response rate and clinical outcome of HCC after first and repeated C TACE performed “on demand”. J Hepatol. 2012;57(6):1258–67CrossRef
Metadata
Title
Immediate Radical Therapy or Conservative Treatments When Meeting the Milan Criteria for Advanced HCC Patients After Successful TACE
Authors
L. Jiang
J. Y. Lei
W. T. Wang
L. N. Yan
B. Li
T. F. Wen
M. Q. Xu
J. Y. Yang
Y. G. Wei
Publication date
01-06-2014
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 6/2014
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-014-2508-2

Other articles of this Issue 6/2014

Journal of Gastrointestinal Surgery 6/2014 Go to the issue